Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend.

[1]  N. Sebire,et al.  Lung metastases in low‐risk gestational trophoblastic neoplasia: a retrospective cohort study , 2019, BJOG : an international journal of obstetrics and gynaecology.

[2]  R. Berkowitz,et al.  Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia? , 2019, Gynecologic oncology.

[3]  A. Gadducci,et al.  Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study. , 2018, Gynecologic oncology.

[4]  R. Berkowitz,et al.  Update on the diagnosis and management of gestational trophoblastic disease , 2018, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[5]  R. Berkowitz,et al.  Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors? , 2017, Gynecologic oncology.

[6]  G. Kenter,et al.  The influence of lung metastases on the clinical course of gestational trophoblastic neoplasia: a historical cohort study , 2016, BJOG : an international journal of obstetrics and gynaecology.

[7]  T. Lawrie,et al.  First-line chemotherapy in low-risk gestational trophoblastic neoplasia. , 2016, The Cochrane database of systematic reviews.

[8]  R. Berkowitz,et al.  Optimal management of low-risk gestational trophoblastic neoplasia , 2015, Expert review of anticancer therapy.

[9]  E. Uberti,et al.  Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women. , 2015, Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia.

[10]  N. Sebire,et al.  Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  M. Danila,et al.  Measurement of Erythrocyte Methotrexate Polyglutamate Levels: Ready for Clinical Use in Rheumatoid Arthritis? , 2010, Current rheumatology reports.

[12]  R. Berkowitz,et al.  Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia. , 2009, Gynecologic oncology.

[13]  A. Mitsuhashi,et al.  Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy , 2005 .

[14]  FIGO staging for gestational trophoblastic neoplasia 2000 , 2002 .

[15]  G. Rustin,et al.  Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Barnhart,et al.  The pharmacology of methotrexate , 2001, Expert opinion on pharmacotherapy.

[17]  J. Lurain,et al.  Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors. , 1995, American journal of obstetrics and gynecology.

[18]  A. Berchuck,et al.  5-day methotrexate for women with metastatic gestational trophoblastic disease. , 1994, Gynecologic oncology.

[19]  S. Ratnam,et al.  Pulmonary metastases in gestational trophoblastic disease: a review of 97 cases , 1988, British journal of obstetrics and gynaecology.

[20]  G. Curt,et al.  Polyglutamation of methotrexate. Is methotrexate a prodrug? , 1985, The Journal of clinical investigation.

[21]  H. Ma,et al.  Methotrexate with citrovorum factor rescue in gestational trophoblastic disease. , 1985, American journal of obstetrics and gynecology.

[22]  R. Berkowitz,et al.  Methotrexate with citrovorum factor rescue as primary therapy for gestational trophoblastic disease , 1982, Cancer.

[23]  J. Weed,et al.  Treatment of nonmetastatic gestational trophoblastic disease: results of methotrexate alone versus methotrexate--folinic acid. , 1982, American journal of obstetrics and gynecology.

[24]  G. Ross,et al.  Primary chemotherapy for nonmetastatic gestational trophoblastic neoplasms. , 1967, American journal of obstetrics and gynecology.

[25]  R. Hertz,et al.  Effect of Methotrexate Therapy upon Choriocarcinoma and Chorioadenoma , 1956, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[26]  R. Berkowitz,et al.  Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. , 2018, Gynecologic oncology.

[27]  J. Lurain.  Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. , 2011, American journal of obstetrics and gynecology.

[28]  H. Aramaki,et al.  Cell-cycle-dependent pharmacology of methotrexate in HL-60. , 2005, Journal of pharmacological sciences.

[29]  K. Bagshawe.  Choriocarcinoma. , 1970, The American journal of medicine.